1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,222 | 0,240 | 06.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.01. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.01. | Tevogen board to evaluate potential special cash dividend | 1 | Investing.com | ||
| 30.01. | Tevogen-Aufsichtsrat erwägt einmalige Sonderausschüttung | 4 | Investing.com Deutsch | ||
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 30.01. | Tevogen Bio Inc: Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders | 157 | GlobeNewswire (Europe) | WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that its Board of Directors has expressed its intention to evaluate... ► Artikel lesen | |
| 29.01. | Tevogen Bio Inc: Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue | 317 | GlobeNewswire (Europe) | WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced that the current time- and individual performance-based long-term... ► Artikel lesen | |
| 12.01. | Tevogen Bio Inc: Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025 | 4 | GlobeNewswire (USA) | ||
| 22.12.25 | Tevogen Bio Inc: Tevogen CEO Donates Shares to Support Education for Underprivileged Children | 3 | GlobeNewswire (USA) | ||
| 19.12.25 | Tevogen Bio Inc: Tevogen CEO Donates Personal Shares to Support Local Fire Department | 3 | GlobeNewswire (USA) | ||
| 11.12.25 | Tevogen Bio Inc: Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock | 5 | GlobeNewswire (USA) | ||
| 09.12.25 | Tevogen Bio Inc: Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine | 1 | GlobeNewswire (USA) | ||
| 08.12.25 | Tevogen Bio Inc: Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook | 6 | GlobeNewswire (USA) | ||
| 14.11.25 | Tevogen Bio Inc: Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q | 225 | GlobeNewswire (Europe) | WARREN, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced the filing of its quarterly report on Form 10-Q for the quarter ended... ► Artikel lesen | |
| 14.11.25 | Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11.25 | Tevogen Bio Inc: Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID | 138 | GlobeNewswire (Europe) | This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk... ► Artikel lesen | |
| 03.11.25 | Tevogen Bio Inc: Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn | 147 | GlobeNewswire (Europe) | WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today issued a statement to provide clarity regarding its accumulated deficit reported... ► Artikel lesen | |
| 29.10.25 | Tevogen Bio Inc: Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress | 382 | GlobeNewswire (Europe) | WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to underscore... ► Artikel lesen | |
| 15.10.25 | Tevogen Bio Inc: Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest | 382 | GlobeNewswire (Europe) | Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of... ► Artikel lesen | |
| 26.09.25 | Tevogen Bio Holdings verstößt gegen NASDAQ-Mindestkursanforderung | 4 | Investing.com Deutsch | ||
| 26.09.25 | Tevogen Bio Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.09.25 | Tevogen Bio Inc: Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell-Based Therapies with 100x PredicTcell Beta Data Expansion | 218 | GlobeNewswire (Europe) | Beta version of PredicTcell expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T cell therapies could reliably bind to their target nearly every... ► Artikel lesen |
1 2 3 4 Weiter >>
68 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 43,170 | -0,70 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Umsatz und Ergebnis des vierten Quartals hätten die Erwartungen... ► Artikel lesen | |
| AMGEN | 325,15 | +0,06 % | Märkte am Morgen: "KI-Realitätscheck", Wolters Kluwer, AMD, Amgen, Walmart, Novo Nordisk | Die Stimmung an den Aktienmärkten ist derzeit sehr, sehr wechselhaft. Das war gestern deutlich zu spüren. Der DAX war bemerkenswert stark in den Handel gestartet, schloss allerdings leicht im Minus.... ► Artikel lesen | |
| NOVAVAX | 6,910 | -0,80 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 15,510 | -3,21 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 662,80 | -0,27 % | REGENERON PHARMACEUTICALS, INC. - 10-K, Annual Report | ||
| INOVIO PHARMACEUTICALS | 1,410 | +0,71 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,550 | -5,49 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 49,320 | +0,28 % | Assessing BioMarin Pharmaceutical: Insights From 5 Financial Analysts | ||
| ARROWHEAD PHARMACEUTICALS | 56,04 | +2,75 % | S&P Dow Jones Indices: Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 | NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:
S&P MidCap 400... ► Artikel lesen | |
| XOMA ROYALTY | 20,600 | -7,21 % | XOMA Royalty Corporation: XOMA Royalty Announces CFO Transition | EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| PHIO PHARMACEUTICALS | 0,920 | +7,39 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference | King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ORAGENICS | 0,750 | +17,98 % | Oragenics, Inc.: Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program | ||
| INSMED | 127,00 | 0,00 % | Insmed Incorporated: Insmed Provides Clinical and Business Update | -Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues... ► Artikel lesen | |
| SWEDISH ORPHAN BIOVITRUM | 37,020 | +0,05 % | Swedish Orphan Biovitrum AB Profit Rises In Q4 | STOCKHOLM (dpa-AFX) - Swedish Orphan Biovitrum AB (SWOBY) announced earnings for its fourth quarter that Increases, from the same period last yearThe company's bottom line totaled SEK1.861 billion... ► Artikel lesen |
Das Unternehmen TEVOGEN BIO HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,224 Euro und damit -3,03 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.